288 related articles for article (PubMed ID: 36123681)
1. Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.
Barchuk A; Cherkashin M; Bulina A; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
BMC Med; 2022 Sep; 20(1):312. PubMed ID: 36123681
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia.
Barchuk A; Bulina A; Cherkashin M; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
BMC Public Health; 2022 Sep; 22(1):1803. PubMed ID: 36138385
[TBL] [Abstract][Full Text] [Related]
3. Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study.
Barchuk A; Bulina A; Cherkashin M; Berezina N; Rakova T; Kuplevatskaya D; Skougarevskiy D; Okhotin A
Respir Res; 2022 Oct; 23(1):276. PubMed ID: 36217139
[TBL] [Abstract][Full Text] [Related]
4. The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac.
Tonnara G; Piselli P; Cimaglia C; Arlotti M; Sacchini E; Manoni S; Zani A; Muccioli F; Laderchi A; Rabini S; Antinori A; Vaia F; Nicastri E; Girardi E
Clin Microbiol Infect; 2022 Dec; 28(12):1636-1643. PubMed ID: 35798146
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.
Kerr S; Vasileiou E; Robertson C; Sheikh A
J Glob Health; 2022 Jul; 12():05025. PubMed ID: 35802764
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
7. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.
Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R
BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
Bruxvoort KJ; Sy LS; Qian L; Ackerson BK; Luo Y; Lee GS; Tian Y; Florea A; Aragones M; Tubert JE; Takhar HS; Ku JH; Paila YD; Talarico CA; Tseng HF
BMJ; 2021 Dec; 375():e068848. PubMed ID: 34911691
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021.
van Ewijk CE; Kooijman MN; Fanoy E; Raven SF; Middeldorp M; Shah A; de Gier B; de Melker HE; Hahné SJ; Knol MJ
Euro Surveill; 2022 Nov; 27(45):. PubMed ID: 36367011
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
[TBL] [Abstract][Full Text] [Related]
13. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
Plumb ID; Fette LM; Tjaden AH; Feldstein L; Saydah S; Ahmed A; Link-Gelles R; Wierzba TF; Berry AA; Friedman-Klabanoff D; Larsen MP; Runyon MS; Ward LM; Santos RP; Ward J; Weintraub WS; Edelstein S; Uschner D
Vaccine; 2023 Apr; 41(15):2596-2604. PubMed ID: 36932031
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
Yang W; Shaman J
medRxiv; 2021 Nov; ():. PubMed ID: 34845460
[TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
Mziou E; Hchaichi A; Letaief H; Dhaouadi S; Safer M; Talmoudi K; Mhadhbi R; Elmili N; Bouabid L; Derouiche S; Bougatef S; Bellali H; Bouafif Ép Ben Alaya N
Vaccine; 2024 Mar; 42(7):1738-1744. PubMed ID: 38365483
[TBL] [Abstract][Full Text] [Related]
16. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
17. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022.
Hoeve CE; de Gier B; Huiberts AJ; de Melker HE; Hahné SJM; van den Hof S; Knol MJ
J Infect Dis; 2023 Aug; 228(4):431-438. PubMed ID: 37093964
[TBL] [Abstract][Full Text] [Related]
18. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
[TBL] [Abstract][Full Text] [Related]
19. Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network.
Tartof SY; Xie F; Yadav R; Wernli KJ; Martin ET; Belongia EA; Gaglani M; Zimmerman RK; Talbot HK; Thornburg N; Flannery B;
Influenza Other Respir Viruses; 2023 May; 17(5):e13143. PubMed ID: 37246146
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
